SOPHiA GENETICS Reports Strong FY25 Results, Guides for FY26 Profitability, Secures Funding, and Wins Key Patent Ruling

summarizeSummary

SOPHiA GENETICS reported robust Q4 and full-year 2025 financial results, demonstrating accelerated revenue growth and improved margins, while providing optimistic 2026 guidance towards Adjusted EBITDA breakeven and positive EBITDA in H2 2027. The company also secured additional liquidity, benefited from a favorable FDA regulatory decision, and achieved an initial win in a patent infringement lawsuit.

check_boxKey Events

• Strong FY2025 Performance & Optimistic 2026 Outlook

  Reported full-year 2025 revenue of $77.3 million, a 19% year-over-year increase, and expanded adjusted gross margin to 74.2%. Guided for 2026 revenue between $92 million and $94 million (20-22% YoY growth) and projected to approach Adjusted EBITDA breakeven by the end of 2026, with positive Adjusted EBITDA in the second half of 2027.

• Strengthened Financial Position

  Secured $15.5 million in net proceeds from its At-The-Market (ATM) program at a weighted-average price of $5.12 per share, and expanded its credit facility by an additional $25 million, enhancing liquidity.

• Favorable Regulatory & Legal Outcomes

  Benefited from the U.S. District Court vacating the FDA's Laboratory Developed Tests (LDT) Final Rule, removing a significant regulatory hurdle. Additionally, achieved an initial win in a patent infringement lawsuit against Guardant Health, with the court ordering Guardant to pay €400,000 in interim costs.

• Strategic Leadership Transition

  Co-founder and CEO Dr. Jurgi Camblong will transition to Executive Chairman, with President Ross Muken appointed as the new Chief Executive Officer, effective July 1, 2026, signaling a planned succession for the next phase of growth.

auto_awesomeAnalysis

This filing presents a highly positive outlook for SOPHiA GENETICS, driven by strong operational performance in 2025 and a clear path to profitability in 2026-2027. The significant revenue growth, expanding gross margins, and increased customer adoption highlight the successful execution of its "land and expand" strategy. The successful capital raise through an ATM program at a premium to the current stock price, coupled with an expanded credit facility, significantly bolsters the company's liquidity and runway. Furthermore, the vacating of the FDA's LDT Final Rule removes a major regulatory uncertainty, and the initial favorable outcome in the Guardant Health patent litigation reduces legal risk. Investors should view these developments as strong indicators of the company's improving financial health and strategic positioning in the precision medicine market. The planned CEO transition appears to be a smooth, internal succession.